12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

therascreen K-RAS regulatory update

Qiagen submitted a PMA to FDA for its therascreen K-RAS test for use as a companion diagnostic for Erbitux cetuximab to treat metastatic colorectal cancer (mCRC). Qiagen expects a decision on the...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >